Pàgina inicial > Resultats de la cerca: Galazka, Andrew
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
9 p, 570.9 KB Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis : An Integrated Analysis of Safety / Giovannoni, Gavin (Queen Mary University of London) ; Galazka, Andrew (Merck. Aubonne. Switzerland. a division of Merck KGaA) ; Schick, Regina (Merck KGaA) ; Leist, Thomas (Jefferson University) ; Comi, Giancarlo (Università Vita-Salute San Raffaele. Ospedale San Raffaele) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Damian, Doris (EMD Serono Research and Development Institute. Inc) ; Dangond, Fernando (EMD Serono Research and Development Institute. Inc) ; Cook, Stuart (The State University of New Jersey) ; Universitat Autònoma de Barcelona. Departament de Medicina
Introduction: Although use of contraception was pre-specified during cladribine clinical trials for multiple sclerosis, some pregnancies did occur. Objective: This analysis reports on pregnancy outcomes in the cladribine clinical development program. [...]
2020 - 10.1007/s40264-020-00948-x
Drug Safety, Vol. 43 Núm. 7 (july 2020) , p. 635-643  
Registre complet - Creative Commons
2.
11 p, 1.1 MB Safety of cladribine tablets in the treatment of patients with multiple sclerosis : An integrated analysis / Cook, Stuart (Rutgers. The State University of New Jersey) ; Leist, Thomas (Jefferson University) ; Comi, Giancarlo (Università Vita-Salute San Raffaele) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Giovannoni, Gavin (Queen Mary University of London) ; Nolting, Axel (Merck KGaA) ; Hicking, Christine (Merck KGaA) ; Galazka, Andrew (Merck. Zone Industrielle de L'Ouriettaz) ; Sylvester, Elke (Merck KGaA) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Treating patients with relapsing multiple sclerosis (MS) with cladribine tablets (two times 4 or 5 days of treatment each year for 2 years) results in long-lasting efficacy, with continued stability in many patients for 4 or more years. [...]
2019 - 10.1016/j.msard.2018.11.021
Multiple Sclerosis and Related Disorders, Vol. 29 (april 2019) , p. 157-167  
Registre complet - Creative Commons
3.
8 p, 915.8 KB Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis / Leist, Thomas (Jefferson University) ; Cook, S. (New Jersey Medical School) ; Comi, Giancarlo (Università Vita-Salute San Raffaele) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Giovannoni, Gavin (Queen Mary University of London) ; Nolting, A. (Merck KGaA) ; Damian, D. (Merck KGaA) ; Syed, S. (Merck KGaA) ; Galazka, Andrew (Merck KGaA) ; Universitat Autònoma de Barcelona
Background: Long-term safety data are of particular interest for any newly approved treatment in multiple sclerosis such as cladribine tablets 10 mg (MAVENCLAD®; 3. 5 mg/kg cumulative dose over 2 years, referred to as cladribine tablets 3. [...]
2020 - 10.1016/j.msard.2020.102572
Multiple Sclerosis and Related Disorders, Vol. 46 (november 2020) , p. 102572  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem